Silence Therapeutics said this week that it has identified the maximum tolerated dose for its siRNA-based cancer treatment Atu027 and that the drug has proven safe and well-tolerated in a nearly complete phase I trial.
Silence Therapeutics last week publicly took issue with Alnylam Pharmaceuticals' claims regarding a European patent opposition, stating that the European Patent Office had limited the “scope and ambiguity” of an Alnylam-controlled patent.
Silence Therapeutics announced this week that it has signed a deal under which Miragen will evaluate its microRNA therapeutic candidates in combination with Silence's cationic lipid-based DBTC delivery technology.
Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.
Silence Therapeutics said this week that the European Patent Office has upheld an amended form of a patent covering protein kinase N beta, which is silenced with the company's phase I cancer drug Atu027.